/
CLDX
$38.22+$0.78 (+2.08%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$2.8B
78M shares
52-week range
$19.52 – $39.16
95% from low
Sector
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Exchange
NASDAQ
CS
Borrow rate
0.25%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$3.79
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.5M | $3.6M | $7.4M | $4.7M | $2.4M | $6.9M | $7.0M | $1.5M |
| Cost of revenue | $66.4M | $42.7M | $42.5M | $53.3M | $82.3M | $118.0M | $163.6M | $0 |
| Gross profit | −$56.9M | −$39.1M | −$35.1M | −$48.7M | −$79.9M | −$111.1M | −$156.5M | $1.5M |
| Gross margin | -596.7% | -1094.3% | -473.4% | -1046.2% | -3389.9% | -1614.5% | -2229.8% | 100.0% |
| R&D | $66.4M | $42.7M | $40.5M | $56.8M | $82.3M | $118.0M | $163.6M | $245.1M |
| Operating income | −$156.4M | −$55.0M | −$63.4M | −$71.2M | −$115.2M | −$154.5M | −$195.1M | −$287.4M |
| EBITDA | −$72.6M | −$49.7M | −$45.6M | −$66.1M | −$104.2M | −$139.0M | −$154.7M | −$255.4M |
| Net income | −$151.2M | −$50.9M | −$59.8M | −$70.5M | −$112.3M | −$141.4M | −$157.9M | −$258.8M |
| Net margin | -1585.1% | -1424.0% | -805.9% | -1516.0% | -4765.6% | -2054.8% | -2248.8% | -17253.3% |
| EPS (diluted) | -14.48 | -3.51 | -2.02 | -1.64 | -2.40 | -2.92 | -2.45 | -3.90 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-4.35 | $-4.56–$-4.02 | 9 |
| 2027 | $11M | $-4.38 | $-5.36–$-3.71 | 9 |
| 2028 | $152M | $-3.11 | $-4.95–$-1.30 | 10 |
| 2029 | $507M | $-0.11 | $-0.35–$0.01 | 4 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.22
Price
$38.22
Implied downside
-99%
Peer comparison
Celldex Therapeutics, Inc
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
www.celldex.com- Employees
- 198
- IPO / List date
- May 15, 1986
- HQ
- HAMPTON, NJ
Held by traders on TradeandTell
No one on the platform currently holds CLDX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 118,488 | $3.2M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2019-02-11 | 1-for-15reverse |
| 2008-03-07 | 1-for-12reverse |
Recent trades on TradeandTell
No one on the platform has traded CLDX yet.
